menu
    • menu
    [{"orgOrder":0,"company":"Belfast Health and Social Care Trust","sponsor":"Araim Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Cibinetide","moa":"Innate repair receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Belfast Health and Social Care Trust","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Belfast Health and Social Care Trust \/ Araim Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Belfast Health and Social Care Trust \/ Araim Pharmaceuticals"},{"orgOrder":0,"company":"Araim Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Cibinetide","moa":"Innate repair receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Araim Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Araim Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Araim Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Araim Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Cibinetide","moa":"Innate repair receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Araim Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Araim Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Araim Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Araim Pharmaceuticals","sponsor":"Claes-G\u00f6ran \u00d6stenson","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Cibinetide","moa":"Innate repair receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"Araim Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Araim Pharmaceuticals \/ Claes-G\u00f6ran \u00d6stenson","highestDevelopmentStatusID":"8","companyTruncated":"Araim Pharmaceuticals \/ Claes-G\u00f6ran \u00d6stenson"}]

    Find Clinical Drug Pipeline Developments & Deals for Cibinetide

    Menu

    Cibinetide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Belfast Health and Social Care Trust

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Belfast Health and Social Care Trust

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cibinetide

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Araim Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Use of ARA290 for the Treatment of Diabetic Macular Oedema

                            Details : ARA290 is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Macular Edema.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            October 04, 2024

                            Lead Product(s) : Cibinetide

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Araim Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Araim Pharmaceuticals

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Araim Pharmaceuticals

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cibinetide

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Innate Repair Activator Cibinetide Shows Potential for Efficacy in Diabetic Macular Edema

                            Details : Cibinetide is a first-in-class synthetic peptide designed to activate innate repair mechanisms in the setting of tissue injury as a result of the inflammatory cascade.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            July 21, 2020

                            Lead Product(s) : Cibinetide

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Araim Pharmaceuticals

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Araim Pharmaceuticals

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cibinetide

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoido...

                            Details : ARA290 is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Neurosarcoidosis.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            January 20, 2014

                            Lead Product(s) : Cibinetide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Araim Pharmaceuticals

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Araim Pharmaceuticals

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cibinetide

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Claes-Göran Östenson

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes)

                            Details : ARA290 is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetes Mellitus, Type 2.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            September 02, 2013

                            Lead Product(s) : Cibinetide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Claes-Göran Östenson

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth